Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

PURPOSE: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups....

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Oncol
المؤلفون الرئيسيون: Scher, Howard I., Morris, Michael J., Stadler, Walter M., Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S., Beer, Tomasz M., Carducci, Michael A., Chi, Kim N., Corn, Paul G., de Bono, Johann S., Dreicer, Robert, George, Daniel J., Heath, Elisabeth I., Hussain, Maha, Kelly, Wm. Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N., Rathkopf, Dana E., Slovin, Susan F., Ryan, Charles J., Sartor, Oliver, Small, Eric J., Smith, Matthew Raymond, Sternberg, Cora N., Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S., Schwartz, Lawrence H., Halabi, Susan, Kantoff, Philip W., Armstrong, Andrew J.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2016
الموضوعات:
Special Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872347/
https://ncbi.nlm.nih.gov/pubmed/26903579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.2702
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة